Open AccessUstekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
Author(s) -
Péter Hoffmann,
Johannes Krisam,
Cyrill Wehling,
Petra Kloeters-Plachky,
Yvonne Leopold,
Nina Belling,
Annika Gauss
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i31.4481
Subject(s) - ustekinumab , medicine , discontinuation , crohn's disease , adverse effect , inflammatory bowel disease , clinical endpoint , refractory (planetary science) , retrospective cohort study , infliximab , surgery , clinical trial , disease , physics , astrobiology
Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use.